Pharmacogenomic and structural analysis of constitutive G-protein coupled receptor activity by Smit, Martine J. et al.
 1 
Pharmacogenomic and structural analysis of constitutive G-protein coupled 
receptor activity  
 
Martine J. Smit1, Henry F. Vischer1, Remko A. Bakker1,3, Aldo Jongejan1, Henk 
Timmerman1, Leonardo Pardo2 and Rob Leurs1 
 
1Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Vrije Universiteit, 
Faculty of Science, Department of Chemistry, de Boelelaan 1083, 1081 HV Amsterdam, the 
Netherlands 2Laboratorio de Medicina Computacional, Unidad de Bioestadistica, Facultad de 
Medicina, Universidad Autonoma de Barcelona, Barcelona, Spain. 3Current address Boehringer 
Ingelheim Pharma GmbH & Co. KG 88397 Biberach, Germany.  
 
Keywords 
G-protein coupled receptors; constitutive activity; inverse agonism 
 
Abstract 
G-protein coupled receptors (GPCRs) respond to a chemically diverse plethora of signal 
transduction molecules. The notion that GPCRs also signal without an external chemical 
trigger, i.e. in a constitutive or spontaneous manner, resulted in a paradigm shift in the 
field of GPCR pharmacology. With the recognition of constitutive GPCR activity and the 
fact that GPCR binding and signaling can be strongly affected by a single point mutation, 
GPCR pharmacogenomics obtained a lot of attention. For a variety of GPCRs, point 
mutations have been convincingly linked to human disease. Mutations within conserved 
motifs, known to be involved in GPCR activation, might explain the properties of some 
naturally occurring constitutively active GPCR variants linked to disease. A brief history 
historical introduction to the present concept of constitutive receptor activity is given and 
the pharmacogenomic and the structural aspects of constitutive receptor activity are 
described.  
 
1. Introduction 
G-protein coupled receptors (GPCRs) form one of the most versatile families of proteins 
to respond to the chemically diverse plethora of signal transduction molecules. Hence, for 
many years this receptor family has been subject of study for human therapeutic benefit. 
Many top-selling drugs from the past and present target the membrane bound GPCRs 
and the pipelines of most pharmaceutical industries are filled with GPCR-targeting 
molecules. With the notion that GPCRs can also signal without an external chemical 
trigger, i.e. in a constitutive or spontaneous manner, a paradigm shift in the field of 
GPCR pharmacology was recently initiated. In this overview we aim to give a brief 
historical introduction to the development of the present concept of constitutive receptor 
activity, whereafter we will indicate the importance of constitutive GPCR activity in 
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relation to the present ideas on the structural basis of GPCR (de)activation and to human 
GPCR pharmacogenomics. 
 
1.1. Early receptor concepts and the molecular basis of drug action. 
GPCRs have been subject of study since the early days of pharmacology and many of 
these investigations have been instrumental to the development of modern concepts of 
receptor theory. The term receptors was initially introduced by Langley (1) and Ehrlich 
(2) to explain the action of respectively nicotine and toxins. Applying the ‘lock – key’ 
model as introduced by Emil Fischer (3), for describing the enzyme-substrate interactions 
in biochemistry, the founders of early pharmacology suggested ‘receptive substances’ to 
exist in order to explain the biological actions of exogenous chemicals on cells. This 
concept matured with the seminal contribution of Clark, stating that the effect of an 
agonist is proportional to the number of occupied receptors. His occupancy theory (4, 5) 
also readily accommodated the difference between an agonist and an antagonist, 
following the ‘lock – key’ principle of Fischer.  
In the 1960s Ariëns and co-workers published their well-known book “Molecular 
Pharmacology” (6), in which the work of Clark was extended. Ariëns et al introduced the 
concept intrinsic activity to explain the observation that not every agonist of a given 
receptor induced the same maximum effect. Compounds reaching the maximum were 
referred to full agonist (intrinsic activity is 1) and other agonists were named partial 
agonist, having an intrinsic activity between 0 and 1. Competitive antagonists were 
supposed to have an affinity for the receptor, but to posses an intrinsic activity of 0. The 
Clark-Ariëns model was extended first by Stephenson (7) and later Furchgott (8, 9) with 
the introduction of drug efficacy and the system-independent concept of intrinsic efficacy.  
The developed concepts have had a great impact in the area of pharmacology and 
drug discovery, especially as the mathematics applied were simple and made it possible 
to calculate in an easy way the affinity and the activity of agonists as well as the affinity 
of antagonists. Looking back it is most remarkable that the ideas about receptor 
activation have been developed during a period of about 75 years, when no real 
information on the biochemical nature of receptors was available, not to speak about the 
molecular mechanisms involved in the generation or transfer of a signal. In the 
Introduction to the book Molecular Pharmacology (6) a receptor was compared with a 
beautiful lady; you may write a letter to her, sometimes she answers but she never 
shows up, though some day she may do so. Moreover, during a conference of the NY 
Academy of Sciences in 1967 Ariëns admitted in a very clear way: “when speaking about 
receptors I am talking about something I do not know anything about” (10).  
It seems that a medicinal chemist (Nauta) and not a pharmacologist, has 
proposed in 1968 for the first time that a GPCR family member might be a protein 
adopting a helical conformation, using the receptor for histamine as his model (11) Using 
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this purely hypothetical model reversible interactions between a ligand and the amino 
acid side chains of the receptor protein were proposed to be involved in the binding of 
both agonists and antagonists (Figure 1A).  
 
1.2 From GPCR gene cloning to constitutive, agonist-independent signaling and 
inverse agonists 
With the introduction of the molecular biology in the area of G-protein coupled receptors, 
it lasted until 1986 before it became clear that the ideas of Nauta were quite close to 
reality (12). We now have high-resolution X-ray structures of at least one GPCR (figure 
1B), rhodopsin {Palczewski, 2000 #4404;Li, 2004 #4403} available and a wealth of 
information on the structure-function relationships of various GPCRs (13), including drug 
binding and GPCR activation (see section 2), has been gathered. In addition, genome 
sequencing projects have permitted to classify the human GPCR sequences into five main 
families: rhodopsin (Class A or family 1), secretin (Class B or family 2), glutamate (Class 
C or family 3), adhesion, and frizzled/taste2 (14). The rhodopsin family is the largest and 
is subdivided in four main groups (α, β, γ, δ) with 13 sub-branches (α: prostaglandin, 
amine, opsin, melatonin, MECA; β: peptides; γ: SOG, MCH, chemokine; δ: MAS, 
glycoprotein, purine, olfactory). These groups include orphan GPCRs, receptors for which 
the ligand and the (patho)physiological function remain unknown. Specialized databases 
of GPCRs can be found at http://www.gpcr.org/7tm (15) and http://www.iuphar-db.org 
(16).  
Our currents insights in GPCR activation have in the last years strongly relied on 
the notion that single point mutations could render GPCRs constitutively active, i.e. could 
signal without the presence of the respective agonist (17-19). At the same time, all these 
studies have also led to the general concept that constitutive GPCR signaling is an 
intrinsic property of most (if not all) GPCR family members and that either GPCR ligands 
or single point mutations can change the equilibrium between inactive and active 
receptor states (18-20). Looking back, it is interesting to notice that already years before 
this general acceptance, research with only limited tools had provided convincing 
experimental evidence for constitutive GPCR signaling. In 1989 Costa and Herz started a 
shift in the paradigm on drug action with a paper, describing antagonists with negative 
intrinsic activity at wild type delta opioid receptors, endogenously expressed in NG108-15 
neuroblastoma cells (21). In this paper, delta antagonists inhibited the basal GTPase 
activity with differential negative intrinsic activity and for the first time GPCR 
pharmacology clearly was faced with intrinsic drug activity going from 1 for agonists to -1 
for antagonists with negative efficacy (now also referred to as inverse agonists). Many 
studies with either wild type or mutant GPCRs have thereafter confirmed the fact that 
GPCR proteins can signal in an agonist-independent, constitutive way and this has been 
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extensively reviewed before (19, 22). The notion of constitutive GPCR activity and the 
bidirectional modulation of GPCR activity by ligands has led to the introduction of a 
simple two-state model of GPCR action. In this model a GPCR protein can shift 
spontaneously between an inactive R to an active R* conformation (23-25). GPCR 
agonists shift the equilibrium to the active R* state, whereas inverse agonists favors the 
inactive R state. The two-state model also explains the observations that some 
antagonists do not affect constitutive GPCR signaling, since these neutral antagonists are 
considered not to affect the thermodynamic equilibrium between the different protein 
conformations. The two-state model and the concept of inverse agonism are now 
generally accepted and have been included in general pharmacology textbooks. 
 
1.3. Constitutive GPCR activity of wild type GPCRs 
As discussed above, the concept of constitutive activity was more or less generally 
accepted following convincing data sets obtained with various constitutively active 
mutant (CAM) GPCRs, which were generated in the lab. Yet, with the increased efforts in 
this area it has become clear that many wild type GPCRs also show considerable levels of 
constitutive activity. This has recently been systematically reviewed by Seifert and 
Wenzel-Seifert (19) and will therefore only be briefly discussed in this review.  
For more than 60 wild type GPCRs from the class A, B and C families constitutive 
activity has now been documented (19). In particular the GPCRs encoded by 
herpesviruses exhibit constitutive activity, providing valuable information on this 
phenomenon that has been linked to the development of disease (see section 3) (26, 
27). Especially the availability of recombinant expression systems has been instrumental 
in this recognition. The extent of constitutive GPCR activity depends on the expression 
level of the respective receptor and the cellular context (19). Constitutive GPCR activity 
might e.g. be boosted by increased expression of G proteins or additional downstream 
effector molecules (19). Nevertheless, for several GPCRs constitutive activity has been 
observed in native tissue or cells (19). Prominent examples are the histamine H3 receptor 
(28, 29) and the melanocortin MCR1 and MCR4 receptors, for which endogenous inverse 
agonists seem to be essential for a proper homeostasis (see also section 3) (30). 
For many of the constitutively active GPCRs also inverse agonists have been 
identified (19). Most of the compounds that were previously characterized as competitive 
antagonists with intrinsic activities of 0, now turn out to be inverse agonists with 
negative intrinsic activities between -1 and 0. Common GPCR antagonists and important 
therapeutic agents, like e.g. adrenergic α1 and β1 receptor antagonists (e.g. prazosin and 
metoprolol) (31), angiotensin AT1 receptor antagonists (e.g. losartan) (32, 33), 
dopamine D2 receptor antagonists (e.g. haloperidol) (34) leukotriene receptor 
antagonists (e.g. montelukast) (35) and histamine H1 and H2 receptor antagonists (e.g. 
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cetirizine and cimetidine) (36, 37) are now all recognized as inverse agonists at their 
respective targets. At present, it is however not very clear if the therapeutic success of 
these molecules is related to their negative intrinsic activity, since neutral antagonists 
have either not yet been identified or have only been tested in a limited number of 
studies. At the serotonin 5HT2C receptor inverse agonist activity of antagonists did not 
correlate with their clinical efficacy as antipsychotics (38), but on the other hand the 
clinical efficacy of serotonin 5HT2A receptor ligands was reported to depend on their 
inverse agonistic activities (39). Similarly, clinical efficacy of the beta blocker metoprolol 
in heart failure seems to be due to its inverse agonist properties as the neutral 
antagonists bucindolol is not effective (20, 40). These studies indicate that in certain 
conditions the therapeutic outcome of inverse agonists and neutral antagonists can 
indeed be different. In this respect, one also has to consider that long-term exposure to 
inverse agonists has been found to lead to upregulation of receptors, which might not 
always be beneficial and a potential reason for e.g. the development of treatment 
tolerance (37, 41, 42). 
 
2. Structural aspects of (constitutive) GPCR activation.  
In contrast to the wealth of available pharmacological data, structural information on 
GPCRs is still scarce. To date, the only crystal structure available is that of the inactive 
state of bovine rhodopsin (43, 44). Five structures of rhodopsin are available at the 
Protein Data Bank, at resolutions of 2.8 Å (PDB identifiers 1F88 and 1HZX), 2.65 Å 
(1GZM), 2.6 Å (1L9H), and 2.2 Å (1U19). Rhodopsin is formed by an extracellular N–
terminus of four β-strands, seven transmembrane helices (TM 1 to TM 7) connected by 
alternating intracellular (I1 to I3) and extracellular (E1 to E3) hydrophilic loops, a 
disulfide bridge between E2 and TM3, and a cytoplasmic C–terminus containing an α-
helix (HX 8) parallel to the cell membrane. Statistical analysis of the residues forming the 
TM helices of the rhodopsin family of GPCRs (Class A) shows a large number of 
conserved sequence patterns (45). This sequence conservation has been used by 
Ballesteros & Weinstein (46) to define a general numbering scheme consisting of two 
numbers: the first (1 through 7) corresponds to the helix in which the amino acid of 
interest is located; the second indicates its position relative to the most conserved 
residue in the helix, arbitrarily assigned to 50: N1.5055 (the superscript represents the 
residue number of rhodopsin, 100% conserved in the family), D2.5083 (94%), R3.50135 
(96%), W4.50161 (96%), P5.50215 (77%), P6.50267 (100%), and P7.50303 (96%). These 
patterns are easily identifiable on a multiple sequence alignment and allow easy 
comparison among residues in the 7TM segments of different receptors. This generic 
numbering scheme of amino acid residues in GPCRs is employed throughout the entire 
manuscript, when referring to the GPCRs of the class A family. 
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The molecular actors involved in the mechanisms of GPCR activation are still not fully 
understood. Farrens et al. have shown that extracellular signals trigger rigid-body 
motions of several, if not all TMs leading to the active state of the receptor (47). It was, 
thus, proposed that the inactive conformation of the receptor is maintained through 
restraining intramolecular interactions impeding these TM motions. Release of these 
constraints is induced by either agonists or constitutive activity-inducing mutations within 
the receptor. The discovery of CAM GPCRs, together with homology models constructed 
from the rhodopsin template has yielded new insights into the mechanism of rhodopsin-
like GPCR activation. Importantly, the sequence conservation pattern of GPCRs within 
this family suggests that this activation mechanism might occur by means of common 
motifs mainly located at the middle part and cytoplasmic ends of the TM helices (45). 
This section describes the different motifs that are involved in GPCR activation. This 
information will be used to explain the properties of naturally occurring GPCR mutants in 
section 3.  
 
2.1. The ionic lock.  
The interaction between R at position 3.50 of the highly conserved (D/E)R(Y/W) motif in 
TM3 with its adjacent D/E residue at position 3.49 and an additional D/E at position 6.30 
near the cytoplasmic end of TM6 (Figure 2c) is known as the ionic lock (48). Charge-
neutralizing mutation of D/E6.30 in TM 6 results in increased constitutive activity (48, 
49). Removal of the ionic interaction between D/E6.30 and R3.50 in this CAM receptor 
facilitates the movement of the cytoplasmic end of TM6 away from TM3 by means of the 
considerable Pro6.50-induced bend angle of TM 6 (44, 48). This type of mutation has 
been described in patients with spontaneous ovarian hyperstimulation syndrome (see 
section 3.1.2). Mutation of D/E3.49 in TM3 to either A or N removing the ionic interaction 
with R3.50 also increases the constitutive activity of rhodopsin (50) and a number of 
structurally related class A GPCRs (48, 51, 52). Thus, removal of this ionic constrain 
makes the side chain of R3.50 free to point towards the protein core (the direction of the 
Cα-Cβ bond). 
 
2.2. The hydrophobic arginine cage.  
Ballesteros et al. (53) suggested that this highly conserved R3.50 is also restrained in the 
inactive conformation by a cage shaped by conserved hydrophobic amino acids at 
positions 3.46 (L:15%; V:8%; I:58%; M:15%) and 6.37 (L:37%; V:24%; I:20%; 
M:5%) (Figure 2c). Removal of these interfering bulky constrains by A or G replacement 
leads to constitutive activity in a number of cases (54-56). 
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2.3. Intracellular helix 8.  
The recent X-ray structure of rhodopsin, revealed the presence of a highly conserved 
helix 8, suggested to be implicated in G protein coupling (43, 57). Figure 2b shows the 
interaction of Y7.53 in TM7 with F7.60 in Hx8 and with the side chain and backbone (via 
water molecule #7) of N2.40 in TM2. Y7.53 and F7.60 are highly conserved in the 
rhodopsin family of GPCRs (Class A) (92% and 68%, see Figure 2) forming the 
NPxxYx5,6F motif (58). This aromatic-aromatic interaction was proposed to be disrupted 
during receptor activation, leading to a proper realigning of Hx8 (58, 59). It has also 
been proposed that the conserved charged (K:17%; R:54%) or polar (Q:11%) side chain 
at position 7.61 has a specific role in stabilizing the free, helix-ending, carbonyls at 
positions 7.54 and 7.55 in TM7 through hydrogen bond interactions (Figure 2b). This 
interaction seems to exert a key role in receptor stabilization, directing in part 
constitutive receptor activity but also the ligand binding profile of the KSHV-encoded 
chemokine receptor ORF74 (see section 3) (60). 
 
2.4. The asparagine of the NPxxY motif.  
The highly conserved N7.49 of the NPxxY motif in TM 7 acts as an on/off switch by 
adopting two different conformations in the inactive and active states (61, 62). N7.49 is 
restrained, in the inactive state, towards TM 6 either via water molecule #9 in rhodopsin 
(63) and other family A GPCRs (Figure 2d) or through the interaction with the 
T6.43D6.44 motif in the glycoprotein hormone receptor family (61, 62) (see section 
3.1.2). It was proposed that upon receptor activation N7.49 adopts the trans 
conformation to interact with D2.50 of the (N/S)LxxxD motif in TM2 (62). It was 
hypothesized that this combination of charged and polar side chains leads to a negative 
electrostatic landscape, which could force relocation of R3.50 from the ionic lock (62, 
64). Any mutation modifying the N7.49 equilibrium, favoring the inactive or active 
conformation, decreases or increases, respectively, the constitutive activity of the 
receptor. 
 
2.5. The hydrophobic asparagine cage.  
Alike to the arginine cage, N7.49 is also located in a cage, restraining its conformation 
towards TM6 in the inactive state, formed by conserved hydrophobic amino acids at 
positions 2.46 (L:91%) and 6.40 (L:14%; V:42%; I:28%; M:5%) (Figure 2d). Removal 
(mutation to A or G) of the bulky and β- or γ-branched amino acids at positions 2.46 in 
rhodopsin (65) and the TSH receptor (62) and 6.40 in rhodopsin (66), serotonin 5HT2AR 
(67), and histamine H1 receptors (64) induces constitutive activity. 
 
2.6. Extracellular loop 2. 
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Recently, Klco et al. have shown that the E2 loop, containing a Cys engaged in a disulfide 
bridge with TM3, acts as a negative regulator of C5a receptor activation (68). Random 
saturation mutagenesis of the amino acids forming this E2 loop shows in nearly 80% of 
the functional receptors an increase of constitutive activity. The high variability with 
respect to length (from 4 to more than 50 residues (45)) and amino acid composition in 
the different GPCR families suggest a non conserved structure of the E2 loop. As of yet it 
is not clear by which molecular mechanism the E2 loop stabilizes the inactive 
conformation of the C5a receptor.   
 
2.7. The W6.48 rotamer toggle switch.  
The recent structure of metarhodopsin I, determined by electron crystallography (69), 
has shown that W6.48 of the CWxP motif in TM 6 undergoes a conformational transition 
from pointing towards TM7, in the inactive state, to pointing towards TM5, in the active 
state, as was previously suggested by experimental studies in rhodopsin (70) and 
computer simulations (71). Rearrangement of W6.48 and the nearby C6.47 decreases 
the highly conserved Pro6.50-induced bend angle of TM 6 (71), moving the cytoplasmic 
end of TM 6 away from TM 3 and disrupting the proposed ionic lock between D/E6.30 in 
TM 6 and R3.50 in TM 3 (48). It has also been suggested that the side chain at position 
3.36 acts as a rotamer toggle switch simultaneously with W6.48 (72, 73), modulating the 
constitutive activity of the receptor. 
 
2.8. A conserved hydrogen bond network linking D2.50 and W6.48.  
D2.50 is involved in maintaining W6.48 pointing towards TM7 in the inactive state of the 
receptor through a conserved hydrogen bond network (44, 69). This conserved network 
varies among GPCR subfamilies. Rhodopsin forms this network through water molecules 
#12 and #10 (Figure 2d, top panel) (44). N7.45, present in 67% of the rhodopsin-like 
sequences but absent in rhodopsin, would be located at the same position as water#10. 
Thus, N7.45-containing receptors are able to form the D2.50··#12··N7.45··W6.48 
network (Figure 2d, middle panel) (72). Similarly, N3.35 (29% of the receptors) would 
be located at the same position as water molecule#12, thus, N3.35/N7.45-containing 
receptors would form the D2.50··N3.35··N7.45··W6.48 network of interactions (Figure 
2d, bottom panel) (74). Disruption of this network by mutating either N7.45 in the H1 
receptor (72) or N3.35 in the AT1 receptor (75) leads to constitutive activity because it 
facilitates the reported conformational transition of W6.48 during receptor activation 
(69). 
 
2.9. Molecular basis of (inverse) agonism.  
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Many wild-type GPCRs display only moderate constitutive activity under normal 
conditions and can be significantly activated by addition of agonists. However, GPCRs can 
in general easily be modified to display enhanced basal activity and often this constitutive 
activity can be linked to diseases (17, 19) (see section 3). In this respect, inverse 
agonists are potentially important therapeutics in the treatment of diseases caused by 
constitutive activity-inducing mutations of the WT receptor.  
The motifs described in sections 2.1-2.8 appear crucial determinants for the 
molecular basis of both agonism as well as inverse agonism. The processes initiated by 
the recognition of the extracellular ligand by the receptor depends to a large extent on 
the type of receptor, since they can be activated by a wide range of extracellular ligands, 
including small neurotransmitters to large hormones. Each subfamily has most likely 
developed specific structural motifs that allow the receptor to accommodate and respond 
to its cognate ligand. However, it seems reasonable to propose that in W6.48-containing 
GPCRs (71% of the rhodopsin-like sequences), ligand binding modifies the conformation 
of W6.48. Upon activation, either by agonists or constitutive activity inducing mutations, 
a conformational transition of W6.48 towards TM5 occurs (see section 2.7). Thus, GPCRs 
possess a small cavity between TMs 5 and 6 to accommodate the side chain of W6.48 in 
the active conformation. This small cavity is formed by the side chains at positions 3.40 
(L:9%; V:25%; I:42%; M:5%), 5.47 (F:70%; Y:11%), and 6.52 (H:29%; F:20%; 
N:19%). The role of the F/Y5.47 and F6.52 aromatic side chains is to further stabilize the 
active conformation of W6.48 by aromatic-aromatic interactions in the face-to-edge 
orientation (Figure 2a, right panel). In addition to the known interaction of aminergic 
ligands with D3.32 in TM 3 and a series of residues at positions 5.42, 5.43 and 5.46 in 
TM 5 (76), an interaction with W6.48 is found for agonists in the histamine H1 receptor 
(Jongejan, unpublished results) and the 5-HT1AR. We propose that agonists trigger this 
conformational transition of W6.48 by means of an explicit hydrogen bond or an 
aromatic-aromatic interaction or both. The right panel of Figure 2a shows a 5-HT1AR 
agonist in the binding pocket of the receptor (77). 
In contrast to the conformational transition triggered by an agonist or a 
constitutive activity-inducing mutation, an inverse agonist will stabilize or reinforce the 
constraints that keep the receptor in its inactive state. The left panel of Figure 2a shows 
the inverse agonist 11-cis-retinal located in this cavity between TMs 5 and 6 in 
rhodopsin. We propose that inverse agonists occupy this small cavity to impede the 
transition of W6.48 towards TM5, thus, decreasing the constitutive activity of the 
receptor. The middle panel of Figure 2a shows the inverse agonist ketotifen in the 
binding pocket of the histamine H1 receptor. The aromatic phenyl moiety of the ligand 
favorably interacts with the aromatic F/Y5.47, W6.48, and F6.52 side chains, and is an 
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important pharmacophoric element of inverse agonists, blocking the conformational 
transition of W6.48. 
 
 
3. Pathophysiological consequences of naturally occurring constitutively active 
GPCR variants.  
With the recognition of constitutive GPCR activity and the notion that GPCR binding and 
signaling can be strongly affected by a single point mutation, GPCR pharmacogenomics 
recently obtained a lot of attention. For a variety of GPCRs, point mutations have been 
convincingly linked to human disease. In this section, we will review the present 
knowledge on naturally occurring mutant GPCRs involved in human disease and linked to 
constitutive activity. Moreover, we will try to explain the GPCR phenotype in relation to 
the presented structural motifs that are thought to be involved in GPCR activation. 
 
3.1. Class A GPCRs 
 
3.1.1. Rhodopsin 
Vision under dim-light conditions by retinal rod photoreceptor cells is mediated by the 
visual pigment rhodopsin. Rhodopsin consists of the apoprotein opsin, a class A GPCR, to 
which an 11-cis-retinylidene chromophore is covalently bound through a protonated 
Schiff-base linkage to the ε-amino group of K7.43296 in TM 7 (78), and E3.28113 in TM3 
acting as a counterion for this linkage (79). Bound 11-cis-retinal acts as an inverse 
agonist by constraining rhodopsin in an inactive conformation in the dark (80). Light 
absorption photoisomerizes 11-cis-retinal into the full agonist all-trans-retinal, which 
initiates consecutive conformational changes in the rhodopsin TM domain (TMD), 
ultimately leading to G protein transducin coupling and subsequent photoreceptor cell 
signaling (80). Autocatalyzed hydrolysis of the Schiff-base linkage results in the 
dissociation of the all-trans chromophore, upon which the dark-state (inactive) rhodopsin 
is regenerated by binding of new 11-cis-retinal to the unoccupied binding site.  
The apoprotein opsin is constrained in a relatively inactive conformation by a salt bridge 
interaction between E3.28113 and K7.43296 (81, 82). Disruption of this salt bridge by 
mutating either E3.28113 or K7.43296 results in constitutive activation of opsin (81). A 
K7.43296E mutation was found in a family with a severe form of autosomal dominant 
retinitis pigmentosa (ADRP) (Table 1), which manifests itself clinically by night blindness 
and a progressive loss of vision due to the degeneration of both rod and cone 
photoreceptor cells (83). This CAM opsin is unable to interact with 11-cis-retinal and 
consequently signals continuously (81). Three other mutations in the opsin gene (i.e. 
G2.5790D, T2.6194I and A7.39292E) have been identified in families with autosomal-
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dominant congenital stationary night blindness (CNSB) (Table 1). Expression of these 
three opsin mutants in heterologous cells results in constitutively signaling in the absence 
of a bound chromophore, by interfering with the salt bridge between E3.28113 and 
K7.43296 (84). However, all three CAM opsins are inactive in darkness when reconstituted 
with 11-cis-retinal and can be activated upon light absorption (85). Interestingly, the 
G2.5790D opsin mutant binds 11-cis-retinal with an ~80-fold slower rate than wild type 
opsin and the T2.6194I and A7.39292E mutants (86). CNSB is a less severe retinal disorder 
in comparison to ADRP, generally resulting in an impaired vision under dim light condition 
and limited or no degeneration of rods. In contrast, continuous activation of the 
photosignaling cascade, either caused by an inability to bind 11-cis-retinal (i.e. CAM 
opsin K7.43296E) or disrupted biosynthesis of 11-cis-retinal (i.e. Rpe65 enzyme 
mutation), is considered to lead to retinal degeneration (84). 
 
3.1.2. Glycoprotein hormone receptors 
The thyroid-stimulating hormone receptor (TSHR), luteinizing hormone/chorionic 
gonadotropin receptor (LHCGR), and follicle-stimulating hormone receptor (FSHR), form 
the subfamily of glycoprotein hormone receptors (GpHRs) (87). These receptors 
distinguish themselves from other class A GPCRs (16) by having a large N-terminal 
exodomain (NTED), which constitutes the selective hormone binding site (88-91). 
Disease-causing CAMs have been found for all three members of this subfamily. 
Interestingly, the TSHR is more susceptible to natural occurring CAMs than the LHCGR 
and FSHR (92). 
 
Thyroid-stimulating hormone receptor 
The thyroid regulates overall body metabolism by secreting thyroid hormones. Pituitary-
derived thyroid-stimulating hormone (TSH) controls growth, differentiation and 
functioning of the thyroid gland by activating the TSHR (93). Autosomal and somatic 
CAMs in the TSHR gene causes familial nonautoimmune hyperthyroidism and thyroid 
adenoma, respectively (94). Both pathological conditions are associated with autonomous 
secretion of thyroid hormones resulting in an acceleration of body metabolism. Hitherto, 
38 natural occurring CAMs have been identified in the TMD of the TSHR, with the bottom 
of TM6 being a hotspot (Figure 3; Table 1) (92). This is rationalized by the fact that the 
TSHR contains the family-specific T at position 6.43 and D at position 6.44, which are the 
main partners of N7.49 in the inactive state of the receptor (61, 62) (see section 2.4). 
Interestingly, also 5 natural occurring CAMs (e.g. S281 of the conserved TYPSHCCAF 
motif) have been identified in the so-called hinge-region of the NTED. In fact, designed 
deletion or mild trypsin digestion of the NTED unmasked the constitutive active character 
of the TSHR TMD (95, 96). Hence, the NTED acts as a tethered inverse agonist to 
 12 
constrain the TMD in a relatively inactive conformation, which is released upon TSH 
binding to the NTED, or can be overruled by point mutations in the hinge region of the 
NTED (see below).  
 
Luteinizing hormone receptor 
The development of the testis and external male genitalia is dependent on testosterone 
production by Leydig cells (97). During fetal development the proliferation, differentiation 
and testosterone production of these cells is induced by LHCGR signaling in response to 
placental-derived chorionic gonadotropin (CG). After birth, the Leydig cells remains 
largely inactive until the advent of puberty when pituitary-derived luteinizing hormone 
(LH) stimulates testosterone production by activating the LHCGR (98). At this stage 
testosterone induces the development of male secondary sex characteristics and 
contributes together with follicle-stimulating hormone (FSH) to maturation of 
reproductive organs and the initiation of spermatogenesis. Hitherto, 17 disease-causing 
CAMs have been identified in the TMD of the LHCGR (Figure 3; Table 1) (92, 99). Most 
CAMs in the LHCGR affects amino acids in TM6, with e.g. D6.30564G releasing the ionic 
lock (see section 2.1), and T6.43577I and D6.44578E/G/Y affecting the NPxxY motif-
mediated receptor activity constraint (see section 2.4). The latter constraint is also 
perturbed in the LHCGR by L3.43H/K/R substitution, due to the formation of a salt bridge 
between the positive charge at position 3.43 and D6.44 (100, 101). Notably, while the 
L3.43H/K mutants are able to respond to the hormone, the L3.43R mutant is 
unresponsive to further hormonal stimulation (101). Mutational analysis revealed that 
also the NTED of LHCGR constrains the TMD in an inactive conformation, however, unlike 
the TSHR no natural CAMs have so far been observed in the LHCGR NTED (102-104). 
Autosomal CAMs in the LHCGR gene causes familial male-limited precocious puberty 
(FMPP) or testostoxicosis, whereas somatic CAMs induce sporadic Leydig cell tumors. 
Male infants inheriting CAMs in the LHCGR gene show accelerated virilization before the 
age of 4 as a consequence of testosterone hypersecretion by Leydig cells (97). Besides 
the precocious development of testosterone-driven male secondary sex characteristics, 
FMPP is associated with an early growth spurt and accelerated bone maturation resulting 
in a short stature.  
Fetal development of female sexual organs, on the other hand, is independent of 
gonadotropins and sex steroid hormones (97). Pubertal maturation of female 
reproductive organs and secondary sex characteristics, on the other hand, is driven by 
estrogens that can only be produced by the ovary upon combined stimulation with FSH 
and LH (see below) (98). This requirement of both FSHR and LHR activity in regulating 
ovary function explains the absence of apparent pathophysiological phenotypes in 
females with a CAM LHCGR (97). 
 13 
 
Follicle-stimulating hormone receptor 
FSH and testosterone regulate together the secretion of spermatogenesis-supporting 
paracrine factors by Sertoli cells in the testis (105). A D6.30567 to G mutation in TM6 of 
the FSHR was identified in a hypophysectomized male patient under treatment with 
testosterone replacement who retained fertility in the absence of FSH and LH (106). This 
FSHR mutant constitutively elevated cAMP levels in transfected Sertoli cells and 
mimicked FSH-like activity upon targeted expression on Sertoli cells in transgenic 
gonadotropin-deficient mice (107-109). The increased constitutive activity caused by this 
particular mutation is attributed to disruption of the ionic lock (see Section 2.1, Figure 
2c). 
In females, the cyclic elevation of plasma FSH levels stimulates recruitment and 
maturation of advanced follicles in the ovary by activating FSHR on the follicle-
surrounding granulosa cells (110). FSHR activity upregulates aromatase enzyme 
expression in these cells allowing the conversion of LH-dependent theca cell-derived 
androgens into estrogens. Estrogens on their turn stimulate pubertal development in 
females and play an essential role in the cyclical preparation of the female reproductive 
tract for conception (98, 110).  
Five different CAMs (i.e. T3.32449I/A, I5.54545T, and D6.30567G/N) in the FSHR gene were 
found in the families in which women exhibit familial spontaneous ovarian 
hyperstimulation syndrome (sOHSS) during pregnancy (49, 111-114). sOHSS is a rare 
syndrome which may lead to life-threatening complications such as massive ovarian 
enlargement, multiple ovarian cysts formation, and ascites (115). Mutations at the T3.32 
position modify the highly conserved hydrogen bond network linking D2.50 and TM6 (see 
section 2.8) and the conformational equilibrium of N7.49 (section 2.4), whereas 
mutations at the D6.30 position modify the ionic lock between TMs 3 and 6 (section 2.1, 
Figure 2c, Figure 3) (49). Besides being constitutively active, these sOHSS-causing FSHR 
mutants display increased responsiveness to CG as compared with the wild type FSHR 
(49, 111-114). This apparent promiscuity is quite surprising given the fact that all CAMs 
were in the TMD and selectivity of glycoprotein hormone receptors for their cognate 
hormones is defined by their NTED (89-91). The increased sensitivity to CG explains the 
clinical manifestation of sOHSS during the first trimester of pregnancy when CG plasma 
levels are highest. Since the increased responsiveness to CG was not associated with an 
increase in affinity it was hypothesized that loosening the intramolecular barrier to 
receptor activation would allow promiscuous receptor activation by low affinity agonists. 
In fact, mutational analysis revealed a direct relation between the level of constitutive 
activity and the responsiveness to promiscuous hormones (49). 
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Hitherto, patients with nonautoimmune hyperthyroidism receive treatment with 
antithyroid drugs (e.g. carbimazole), that interferes with thyroid hormone synthesis. 
Although antithyroid drugs are efficient in controlling hyperthyroidism, they do not 
prevent thyroid enlargement (116). Consequently, antithyroidal drug therapy is usually 
followed by thyroidectomy. FMPP is currently controlled by either inhibiting adrenal and 
testicular androgen biosynthesis using the P450 cytochrome inhibitor ketanazole, or 
combined administration of an androgen receptor antagonist (spironolactone) and 
aromatase inhibitor (testolactone) (117, 118). Recently, specific non-peptide antagonists 
and agonists have been identified for the FSHR and LHCGR (119-124), with therapeutic 
potential for anticonception and assisted-reproduction, respectively. Hence, identification 
of non-peptide inverse agonists specifically inhibiting constitutive signaling of LHCGR, 
FSHR, or TSHR may therefore be a matter of time. 
 
3.1.3. Growth hormone secretagogue receptor (GHSR) type 1a 
The GHSR-1a receptor modulates growth hormone release upon activation by the peptide 
ghrelin, a potent hunger signal that stimulates appetite (125). The GHSR-1a has 
attracted considerable interest in recent years for its role in satiety.  Modulators of 
GHSR-1a activity or GHSR-1a expression (126) are consequently investigated as 
potential therapies for the treatment of obesity (127). 
The GHSR-1a has been shown to possess a high level of constitutive activity in vitro 
(128). The recent discovery of a naturally occurring mutant GHSR-1a receptor (A204E) 
that lacks constitutive activity, but not its capacity to mediate agonist induced signaling, 
support a physiological role for the constitutive GHSR-1a activity. The GHSR-1a A204E 
mutation results in a functional receptor that lacks constitutive activity and leads to a 
syndrome characterized by a short stature and might be related to obesity that develops 
during puberty (129). The presence of this mutation in the GHSR-1a receptor, as well as 
a GHSR-1a F6.51279L mutation  were described previously to occur in obese individuals 
(130). Both the A204E and F6.51279L mutant GHSR-1a receptors exhibit loss of 
constitutive receptor activity, while maintaining the capacity to mediate ghrelin-induced 
signaling events (128, 129). Whereas the A204E mutation occurs in the E2 loop (see 
section 2.6), the F6.51279L mutation modifies the conserved aromatic cluster CWxPFF 
motif in TM 6 (section 2.7). 
The loss of constitutive activity results in the expected phenotype with respect to growth, 
while this is not the case with respect to appetite and energy expenditure (131). These 
findings indicate the existence of complex interactions and potential compensatory 
pathways to compensate for this loss of function in the GHSR-1a receptor. Possibly, 
activation of GPR39, recently deorphanized as the receptor for the peptide hormone 
obestatin, derived from the same gene as ghrelin, might account for this compensatory 
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pathway. Activation of GPR39 has opposite effects on food intake and weight gain 
compared to stimulation of the GHSR-1a receptor (132).  
 
3.1.4. Melanocortin receptors 
The family of melanocortin receptors and the existence of endogenous inverse agonists 
acting at these receptors have greatly strengthened the concept of constitutive receptor 
activity and have further supported its physiological relevance. The melanocortin system, 
which controls pigmentation and body weight, encompasses a family of five receptors. 
Both the melanocortin-1 receptor (MC1R) and 4 (MC4R) illustrate the occurrence and 
relevance of constitutive receptor activity in vivo. MC1R was originally called melanocyte 
stimulating hormone (MSH) receptor and is expressed in cutaneous and hair follicle 
melanocytes. Stimulation of MC1R by MSH as well as by adrenocorticotrophin (ACTH) 
leads to a stimulation of melanogenesis, through an increased transcription of genes 
involved in the production of eumelanic dark pigments. In contrast, modulation of the 
MC1R by the naturally occurring inverse MC1R agonist agouti, a paracrine factor 
expressed in the skin, induces the production of the yellow pigment pheomelanin (133). 
The MC1R exhibits a high level of constitutive activity accounting for the phenomenon of 
inverse agonism. Over 60 naturally occurring MC1R variants, located throughout the 
receptor, have been described (reviewed in (134, 135)). These mutant receptors are 
often associated with clearly visible phenotypes, showing abarrent cell surface 
expression, decrease or further increase in constitutive activity. The latter unmasks 
inverse agonistic properties of endogenous peptides (reviewed in (134, 135)).  
The MC4R controls body weight and in the brain constitutive MC4R activity is inhibited by 
agouti-related protein (AgRP) (136). MC4R knock-out, the presence of inactivating 
mutations in the NTED (R7H, T11A, T11S, R18C, R18H, R18L), in the I2 loop (A154D, Q156P) or 
pharmacological inhibition of the MC4R results in obesity (137, 138). A cluster of 
naturally occurring mutations in the NTED of the MC4R in obese patients have been 
identified. The resultant mutant MC4R receptors exhibit a reduced constitutive activity, 
which led to the suggestion that the NTED in the receptor functions as an intrinsic partial 
agonist that contributes to the level of constitutive MC4R activity (30, 139). The activity 
of the MC4R is modulated through the opposing effects of the anorexigenic agonist α-
MSH and the orexigenic inverse agonist AgRP (139, 140). Whereas MC4R agonists are of 
interest for the potential treatment of obesity, inverse MC4R agonists might exhibit 
favorable characteristics for the treatment of e.g. cancer-associated cachexia (141).  
While no constitutively activating MC4R mutations have been reported to date from 
anorexia nervosa patients (142), one AgRP gene polymorphism has been associated with 
anorexia nervosa (143, 144). In fact mutations in MC4R are thought to be the most 
common genetic cause of obesity. Besides the inactivating mutations within MCR4, there 
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are also mutant MC4Rs found to be retained in the cytoplasm and poorly expressed 
(145), or that respond poorly to MSH (146). Yet, the overall influence of mutations in the 
MC4R on obesity is not clear, a variety of MC4R mutations found in non-obese individuals 
also exhibit loss-of-function characteristics, while impairment of cell surface expression 
for some mutant MC4R linked to the occurrence of obesity was not confirmed (142). 
 
3.1.5. Virus-encoded GPCRs 
Besides the naturally occurring GPCR variants described in previous sections 3.1.1-3.1.4 
a relatively novel and intriguing class of GPCRs, encoded by the herpesviruses, exhibit 
marked constitutive activity. Altogether, the herpes- and poxviruses encode over 40 
GPCRs, most of them displaying homology to chemokine receptors (147), known to be 
implicated in the regulation of the immune response (148). Although the roles of these 
viral-encoded receptors have not been revealed yet, they are believed not only to 
subvert the immune system but also to contribute to virus-induced pathogenesis. A large 
number of these viral GPCRs have acquired additional properties compared to their 
cellular counterparts, including the ability to bind a broad spectrum of chemokines, 
couple to a variety of G proteins and display high constitutive activity (26, 27, 149). In 
particular, the GPCRs encoded by the Kaposi’s sarcoma associated herpes virus (KSHV), 
Epstein-Barr virus (EBV) and human cytomegalovirus (HCMV) illustrate well the 
(patho)physiological importance of constitutive receptor activity. 
KSHV, implicated in the development of Kaposi Sarcoma (KS), encodes the GPCR ORF74 
(150). ORF74 shows highest homology to the human chemokine receptor CXCR2. This 
viral GPCR binds a broad spectrum of chemokines and is unlike CXCR2 able to 
constitutively activate a variety of signal transduction cascades linked to proliferation 
(see (151) for references). Expression of ORF74 in vivo within haemopoetic or endothelial 
cells leads to the development of angioproliferative lesions that morphologically resemble 
KS lesions (152). Not only modulation of ORF74 activity by endogenous chemokines, but 
also constitutive activity of ORF74 appears to play an important role in the progression of 
Kaposi’s Sarcoma-like lesions in ORF74 transgenic mice. The constitutive activity of 
ORF74 has been attributed to the absence of residues which normally are thought to be 
involved in GPCR activation (see section 2) (153). Re-introduction of these motifs did 
however not result in significant changes in basal activity of the receptor. Mutation of 
N2.5092 to the corresponding D (see section 2.8) did not lead inactivation of the ORF74 
receptor. Interestingly, substitution of the neighboring L2.4991 with an Asp did result in 
loss of constitutive activity (153). Expression of this constitutively inactive mutant in vivo 
(L2.4991D) completely prevented development of a KS-like disease in transgenic mice 
(154), emphasizing the relevance of constitutive receptor activity. Of particular interest 
are the mutations within helix 8 that besides influencing constitutive activity also have a 
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remarkable effect on the ligand binding properties of KSHV-ORF74 (section 2.3, Figure 
2b) (60). Constitutive activation of Akt by ORF74 e.g. plays a crucial role in ORF74 
mediated sarcomagenesis (155, 156). Moreover, ORF74-induced upregulation and 
release of pro-angiogenic factors, including proinflammatory cytokines and chemokines 
appear sufficient to drive angioproliferative tumor formation by autocrine or paracrine 
stimulation (156-159). Hence, this constitutively active viral chemokine receptor ORF74 
seems to be implicated in the pathology of KS. 
In addition, EBV, known to be associated with many lymphoproliferative diseases such as 
infectious mononucleosis, Burkitt’s lymphoma (BL) and nasopharyngeal carcinoma (NPC), 
encodes a GPCR referred to as BILF1 (160, 161). Like ORF74, BILF1 constitutively 
activates signaling to NFκB and CRE, both implicated in proliferative signaling (161). The 
increased activation of signaling pathways was also apparent in EBV-positive 
lymphoblastoid B cell lines (161), suggesting a role for BILF1 in EBV-related proliferative 
diseases.  
The human cytomegalovirus (HCMV) encodes even four GPCRs (US27, US28, UL33 and 
UL78), which also show highest homology to chemokine receptors. Both US28 and UL33 
alter cellular signaling in a constitutively active manner, when ectopically expressed and 
more importantly after HCMV infection, as shown using HCMV US28 and UL33 deletion 
strains (162-165). Through promiscuous G protein coupling US28 and UL33 activate 
multiple signaling pathways, including effectors and transcription factors within infected 
cells. In contrast to other GPCRs, US28 does not possess ‘the ionic lock’, offering a 
possible explanation for the observed constitutive activity. Substitution of R3.50129 of the 
conserved DRY-motif with an Ala, removes an important determinant for G protein 
coupling, resulting in the loss of constitutive activation of G protein-mediated signaling 
pathways (Waldhoer 2003 3879). Moreover, nonpeptidergic ligands have been identified 
that acts as inverse agonist (e.g. VUF2274), inhibiting basal US28 signaling in 
heterologous systems but also infected cells. In addition, VUF2274 was shown to partially 
inhibit HIV-1 entry into US28-expressing cells (166). 
HCMV has been associated with chronic diseases including e.g. vascular diseases (167) 
and malignancies (168, 169). Since the CMV-encoded receptors US28 and UL33 
constitutively activate transcription factors, implicated in inflammatory events associated 
with e.g. atherosclerosis and tumorigenesis (170), these receptors are believed to play a 
role in onset or progression of these HCMV-related pathologies.  Recently, we have 
observed that expression of US28 induces transformation and tumorigenesis in vivo, 
suggesting that US28 might act in a concerted manner with other oncogenic HCMV-
encoded proteins (171) to enhance tumorigenesis (172). The use of constitutively 
inactive mutants, the development of adequate disease model systems and use of 
recently identified inverse agonists targeting the HCMV-encoded receptors (173) will 
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serve as important tools to determine the (patho)physiological relevance of constitutive 
receptor activity of these receptors in vivo model systems.   
 
3.2. Class B/C and Frizzled family GPCRs 
In contrast to GPCRs belonging to the rhodopsin family of GPCRs (class A), little 
information is available on structural determinants involved in GPCR activation and 
inverse agonism of the class B/C and Frizzled GPCR families. Nonetheless, examples of 
natural occurring CAMs in these receptor families will be discussed below. 
 
3.2.1 Parathyroid hormone (PTH)-related peptide (PTHrP) type 1 receptor 
(PTHR1) 
The PTHR1 for PTH and PTHrP belongs to the class B GPCRs. This receptor is highly 
expressed in bone and kidney and mediates the PTH-dependent regulation of mineral ion 
homeostasis, including the circulating concentrations of calcium and phosphorous (174). 
Mutation of a histidine at the bottom of TM2 (H223R), of a threonine in TM6 (T410R and 
T410P) and of an isoleucine in TM7 (I458R) of the human PTH-receptor have been reported 
to be associated with constitutive PTH receptor activation in Jansen-type metaphyseal 
chondrodysplasia, a rare disorder that is typically characterized by severe growth plate 
abnormalities that lead to short-limbed dwarfism (175 ). The high level of constitutive 
activity of the mutant receptor is thought to result in hypercalcemia and 
hypophosphatemia, and most likely the abnormal formation of endochondral bone (175). 
 
3.2.2 Ca2+-sensing receptor (CaSR) 
Extracellular Ca2+ (Ca2+o) homeostasis is regulated by the parathyroid hormone (PTH), 
which is produced by parathyroid glands. PTH stimulates the (re-)absorption of Ca2+ by 
the kidney and intestine, and Ca2+ mobilization from bone. Fluctuation in Ca2+o levels is 
detected by the Ca2+-sensing receptor (CaSR), which is abundantly expressed on PTH-
producing chief cells in the parathyroid gland and tubular cells in the kidney (176). Like 
most other members of the class C GPCR family (16), the CaSR contains a Venus-flytrap-
like ligand-binding domain within its large NTED (177, 178). Activation of the CaSR by 
elevated Ca2+o levels inhibits PTH secretion by the parathyroid chief cells and stimulates 
the urinary Ca2+ excretion, as such restoring the homeostatic Ca2+o concentration (176). 
Hence, the CaSR is crucial for the negative feedback regulation of the Ca2+o homeostatis. 
Activational mutations in the CaSR results in hypoparathyroidism, which is clinically 
manifested as autosomal dominant hypocalcemia (ADH). To date, 35 sporadic or familial 
ADH-causing mutations have been identified in the CaSR (179). Only one of these 35 
activating mutations (i.e. A843E in TM 7) appeared to be a true CAM by inducing ligand-
independent basal signaling (180, 181). The other activating mutations involve increased 
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receptor sensitivity to Ca2+o, without affecting basal signaling, showing receptor 
activation at inappropriately low Ca2+o concentrations (178). 
 
3.2.3. Smoothened 
Smoothened is a GPCR that is thought to signal via families of heterotrimeric G proteins 
and possibly via non-G protein signaling pathways (182) and forms a distinct group 
within the family of GPCRs together with the frizzled receptors. This receptor is kept in an 
inactive state through its interaction with the transmembrane protein Patched (Ptc), the 
receptor for lipid-modified secreted glycoproteins of the Hedgehog (Hh) family. Binding of 
Hh to Ptc activates Ptc to release the catalytic repression of Ptc on smoothened activity to 
unleash the constitutive activity of smoothened (183). Whereas the Hh pathway plays 
fundamental roles during pattern formation in animal development, the dysfunction of 
Hh-pathway components are frequently associated with congenital disorders and cancer 
(184-187). Cyclopamide, a teratogen found in the Veratrum californicum plant that 
blocks cholesterol synthesis, is an Hh/smoothened inhibitor, and induces regression of 
skin tumors (188). The effects of oncogenic mutations in TM7 (S537N and W539L) and 
constitutively activating mutations in TMs 6 (G460Y) and 7 (S537T, G533L, G533H, G533T, G533Y, 
G533S, and G533A) in smoothened and Ptc can be reversed by cyclopamide treatment (189). 
Hence, modulators of smoothened activity appear promising for the treatment of a 
variety of cancers as well as psoriasis (188-191). Consequently, several smoothened 
modulators have recently been described (192-194). 
 
4. Concluding remarks 
Not only mutational analysis of wild type GPCRs, but also those natural occurring CAMs 
that are associated with disease, have contributed to our knowledge on constitutive 
receptor activity. Specific conserved domains within the receptor appear essential in the 
regulation of (spontaneous) signaling. In particular, mutational changes near the 
interface at the bottom of TM3 or top of TM6 often result in increases of constitutive 
activity (19). Analogous to these observations, an agonist is believed to relieve the 
receptor from these intrinsic constraints, inducing a movement of the bottom of TM6 (47, 
195). Mutations in these regions are found in a number of GPCRs, e.g. of the 
glycoprotein family, that are associated with human diseases. Disruption of the constraint 
within those receptors, leads to constitutive receptor activity and consequently to the 
development of disease. In particular, in these cases the use of inverse agonists is in 
particular definitely the choice of treatment.  
For some GPCRs, autoantibodies have been identified that recognize epitopes on the 
second, most variable, extracellular loop, causing pathologies (see for refs (20, 22). The 
fact that the second extracellular loop seems to be in part implicated in constitutive 
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activity of some receptors (68), might explain the observed effects of autoantibodies. 
These antibodies appear indeed to influence receptor activity and some even display 
agonsitic activity (196) that can be counteracted by inverse agonists.  
Numerous of the clinically used drugs acting on GPCRs, in particular those of the 
bioaminergic families, are in fact inverse agonists. Their inverse agonistic properties have 
in particular been shown in recombinant systems, but also in native systems (21, 29) 
Inverse agonists inhibit constitutive signaling initially, yet chronic use might lead to 
receptor upregulation and sensitization. Taken together, the importance of inverse 
agonism for the clinical efficacy of drugs targeting receptors with low or high constitutive 
activity is just beginning to emerge and requires further attention.  
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Figure Legends 
Figure 1. A) Early model of histamine receptor and the binding of 4-
methyldiphenhydramine to a phenylalanine residue through a π - π interaction 
mechanism by Nauta (197). B) Crystal structure of bovine rhodopsin (PDB code 1GZM) 
(44). Retinal shown using CPK representation.  
 
Figure 2. Crystal structure of bovine rhodopsin (PDB code 1GZM) (44). The color code of 
the α-carbon ribbons is: TMs 1 (crimson), 2 (goldenrod), 3 (dark red), 4 (gray), 5 (red), 
6 (orange), and 7 (blue), and Hx8 (blue). The positions of the amino acids involved in 
receptor activation, together with their conservation pattern in the rhodopsin family of 
GPCRs (45) are shown. The standardized nomenclature of Ballesteros and Weinstein is 
employed (46). (a) Molecular basis of agonism and inverse agonism. Detailed view of the 
inverse agonists 11-cis-retinal (left panel) and ketotifen (middle panel) in a cavity 
between TMs 5 and 6 as observed in the crystal structure of rhodopsin (44) and a 
computational model of the histamine H1 receptor, respectively. The 5-HT1AR agonist (the 
naphtyl ring of the ligand is not shown for clarity) triggers the conformational transition 
of W6.48 towards TM5 by an explicit hydrogen bond (right panel) (77). Ligands are 
shown in dark green. (b) Network of interactions involving highly conserved amino acids 
within TM2, TM7 and Hx8 in rhodopsin (59, 60). (c) The ionic lock (48) and the 
hydrophobic arginine cage (53) between TMs 3 and 6 in rhodopsin. (d) Proposed 
hydrogen-bond network linking D2.50 and W6.48 in the inactive conformation of 
rhodopsin (top panel) (44), the histamine H1 receptor (middle panel) (72), and δ opioid 
receptor (bottom panel) (74). N7.49 of the NPxxY motif is restrained towards TM6 via 
water molecule #9 in rhodopsin (63) and hydrophobic amino acids at positions 2.46 and 
6.40 forming the asparagine cage (62, 64). 
These figures were created using MolScript v2.1.1 (198) and Raster3D v2.5 (199). 
 
Figure 3. Snake plot of a consensus GpHR showing the NTED to which glycoprotein 
hormones bind and the TMD. Amino acid residues that are conserved in FSHR, LHCGR 
and TSHR are indicated. Conserved cysteine residues in the TMD, the N-terminal Cys 
domain and C-terminal Cys domain of the NTED that are involved in disulfide bridges, are 
indicated by circles with a black background. The hormone binding domain in the NTED is 
boxed and β-strands of the leucine-rich repeats and N-terminal Cysteine rich domain that 
form the binding surface are represented by arrows (89). The hormone-binding domain is 
connected to the TMD by the so-called hinge region, which is of variable length between 
the 2nd and 4th conserved C-terminal Cys residues in the TSHR, LHCGR, and FSHR. The 
TM helix boundaries correspond to the bovine rhodopsin crystal structure (PDB code 
1GZM) (44). The conserved amino acid in each TM helix of class A GPCRs is indicated 
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according to the Ballesteros & Weinstein numbering scheme (See section 2) (46). 
Locations of natural occurring GpHR CAMs (see Table 1) are indicated: yellow – FSHR; 
orange – LHCGR; pink – TSHR; blue – LHCGR/TSHR; green – LHCGR/TSHR/FSHR. 
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Table 1. Constitutive active GPCR mutants associated with pathophysiological conditions 
 
Family GPCR OMIM1 inheritance phenotype2 CAM2,3 
A rhodopsin 180380 autosomal dominant congenital stationary night blindness G2.57D, T2.61I, A7.39E 
   autosomal dominant retinitis pigmentosa K7.43E 
A TSHR 603372 autosomal dominant nonautoimmune hyperthyroidism G1.49S, M2.53V, S3.36R, V3.40A, A6.34V, 
     L6.40F, P6.50S, N650Y [EL3], N7.45Y, C7.47Y 
   de novo (germline) nonautoimmune hyperthyroidism S281N [NTED], M2.43T, S3.36N, V5.54L/F, F6.42L 
   somatic hyperfunctioning thyroid adenoma S281T/N/I [NTED], M2.43T, I486M [EL1]  
     L3.43R, I568T [EL2], Y5.58N, D6.30G, A6.34V/I/S 
     L6.40F, F6.42L/C/I, T6.43A/P/I, D6.44A/E/H/Y 
     P6.50S, V656F [EL3] 
   somatic hyperfunctioning thyroid carcinoma M2.43T, I486F [EL1], A6.34V, T6.43A/I, D6.44H, L7.52V 
   autosomal dominant euthyroid hyperthyrotropinemia R310C [NTED], C390W [NTED] 
A LHCGR 152790 autosomal dominant familial male-limited precocious puberty L1.41P, A1.46V, M2.43T, L3.43R, I5.54L, D6.30G, A6.34V 
     M6.37I, A6.38V, I6.41L, T6.43I, D6.44E/G/Y, C6.47R, M6.48G 
   somatic Leydig cell adenoma  D6.44H 
A FSHR 136435 autosomal dominant spontaneous ovarian hyperstimulation syndrome T3.32A/I, I.5.54T, D6.30N 
    FSH-independent spermatogenesis D6.30G 
B PTHR1 168468 autosomal dominant Jansen's metaphyseal chonfrodysplasia H223R [TM2], T410R/P [TM6], I458R [TM7] 
C CaSR 601199 autosomal dominant autosomal dominant hypocalcemia A843E [TM7] 
1OMIM: Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University 
(Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), World Wide Web URL: 
http://www.ncbi.nlm.nih.gov/omim/ 
2Pathophysiological conditions associated with constitutively active mutant (CAM) GPCRs were collected from the OMIM, Glycoprotein-
hormone Receptor Information System (GRIS) (92), and Human Gene Mutation Database (HGMD) (200) databases, see references herein 
for more specific details. 
3Amino acid mutations are indicated using the Ballesteros & Weinstein numbering if situated in the TM helices of class A GPCRs (see section 
2 for details on this numbering scheme). Amino acid mutations that are situated elsewhere in class A GPCRs, or mutations in class B or C 
GPCRs are represented by residue number and the location is indicated between brackets.  
TSHR = thyroid-stimulating hormone receptor; LHCGR = luteinizing hormone/chorionic gonadotropin receptor; FSHR = follicle-stimulating 
hormone receptor; PTHR1 = parathyroid hormone -related peptide type 1 receptor; CaSR = Ca2+-sensing receptor; NTED = N-terminal 
exodomain; EL1, -2, -3 = extracellular loop 1, 2, and 3, respectively; TM1-7 = transmembrane helices 1 to 7. 
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